Immuneering Corporation (IMRX) News
Follow Immuneering Corporation (IMRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Immuneering Q3 Loss Widens Beyond Expectations on R&D Spending
EQUITY | Oct 29, 2026, 08:27 PM UTC
M
Immuneering Reports $24.2 Million Q3 Net Loss, Cash Runway Into Q4 2028
Immuneering reported a third-quarter 2026 net loss of $24.2 million, or $0.37 per share, versus a $15.0 million loss a year earlier. Cash, cash equivalents and marketable securities totaled $166.1 million at September 30
EQUITY | Oct 29, 2026, 08:21 PM UTC
L
Immuneering Corporation (IMRX) Shares AACR Data Supporting Atebimetinib in Pancreatic Cancer
Immuneering reported AACR data indicating atebimetinib + mGnP was linked to body mass preservation and tumor volume reduction in first-line pancreatic cancer, echoing prior Phase 2a findings and supporting its ongoing Ph
EQUITY | Sep 28, 2026, 11:32 AM UTC
L
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study -- Patients with stable or increased weight at three months had sig
NEWS | Sep 28, 2026, 11:32 AM UTC
H
Immuneering to Present at the ESMO Congress 2026
Trial in progress poster will highlight the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer patients -NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation NASDAQ
GEOPOLITICS | Sep 24, 2026, 11:32 AM UTC
H
IMRX - Immuneering to Present at the ESMO Congress 2026
IMRX - Immuneering to Present at the ESMO Congress 2026
GEOPOLITICS | Sep 24, 2026, 11:30 AM UTC
L
IMRX: Atebimetinib shows 17.3 months median OS in first-line pancreatic cancer with improved tolerability
Phase III trials of atebimetinib in first-line pancreatic cancer are progressing, with strong phase II data showing 17.3 months median OS and improved tolerability. The drug's unique mechanism addresses prior MEK inhibit
NEWS | Sep 14, 2026, 10:13 PM UTC
L
IMRX: Atebimetinib shows best-in-class survival and tolerability in first-line pancreatic cancer trials
Phase III trials of atebimetinib in first-line pancreatic cancer are progressing, with phase II data showing a median OS of 17.3 months and strong tolerability. The drug's unique mechanism and reduced toxicity differenti
NEWS | Sep 14, 2026, 09:51 PM UTC
L
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months -- New analyses evaluate the overall survival implic
EQUITY | Sep 10, 2026, 11:32 AM UTC
L
IMRX - Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
IMRX - Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
EQUITY | Sep 10, 2026, 11:30 AM UTC
L
Immuneering management plans to attend upcoming investor conferences
Immuneering Corporation (IMRX) said management plans to participate in upcoming investor conferences, with further details to follow.
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
IMRX - Immuneering to Participate in Upcoming Investor Conferences
IMRX - Immuneering to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 08:05 PM UTC
L
IMRX - Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - C
IMRX - Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
REGULATION | Aug 26, 2026, 09:16 PM UTC
L
IMRX - Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
IMRX - Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
EARNINGS | Aug 05, 2026, 11:30 AM UTC
L
IMRX - PR: Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS
IMRX - PR: Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition Link To Press Release
EQUITY | Jul 21, 2026, 08:15 PM UTC